Recent News

• 10.01.2025 - Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer
• 09.29.2025 - Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN
• 09.04.2025 - Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025
• 08.25.2025 - Climb Bio to Present at Upcoming September 2025 Investor Conferences
• 08.12.2025 - Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

Recent Filings

• 10.01.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.01.2025 - 8-K Current report
• 10.01.2025 - 3 Initial statement of beneficial ownership of securities
• 09.29.2025 - 8-K Current report
• 09.29.2025 - EX-99.1 EX-99.1
• 09.18.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 08.12.2025 - 8-K Current report
• 08.12.2025 - EX-99.1 EX-99.1
• 08.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.11.2025 - 4 Statement of changes in beneficial ownership of securities